Filtered By:
Condition: Diabetes
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date.
Order by Relevance | Date
Total 353 results found since Jan 2013.
Effect of the Dual Dual Glucose-Dependent Insulinotropic Peptide/Glucagon-Like Peptide 1 Receptor Agonist Tirzepatide on Lipid Profile and Waist Circumference: A Systematic Review and Meta-analysis
Clin Ther. 2023 Jul 14:S0149-2918(23)00200-X. doi: 10.1016/j.clinthera.2023.06.008. Online ahead of print.ABSTRACTPURPOSE: Tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide 1 receptor agonist, has been approved by the US Food and Drug Administration for the treatment of type 2 diabetes. The purpose of this meta-analysis is to evaluate the impact of tirzepatide on lipid profile and waist circumference (WC), both of which are risk factors of cardiovascular diseases.METHODS: The PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov databases were systematically searched ...
Source: Clinical Therapeutics - July 16, 2023 Category: Drugs & Pharmacology Authors: Dan Yu Shanshan Shen Jinghong Zhang Qijun Wang Source Type: research
Nonalcoholic Fatty Liver Disease and Omega-3 Fatty Acids: Mechanisms and Clinical Use
We describe NAFLD prevalence and pathophysiology as well as current NAFLD therapies. We also present evidence from clinical and preclinical studies that evaluated the capacity of C20-22 ω3 PUFAs to treat NAFLD. Given the clinical and preclinical evidence, dietary C20-22 ω3 PUFA supplementation has the potential to decrease human NAFLD severity by reducing hepatosteatosis and liver injury. Expected final online publication date for the Annual Review of Nutrition, Volume 43 is August 2023. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.PMID:37207355 | DOI:10.1146/annurev-nutr-061021-030223
Source: Annual Review of Nutrition - May 19, 2023 Category: Nutrition Authors: Melinda H Spooner Donald B Jump Source Type: research
Prevalence of Potential Drug-Drug Interactions With Ritonavir-Containing COVID-19 Therapy in the United States: An Analysis of the National Health and Nutrition Examination Survey
This study combined National Health and Nutrition Examination Survey (NHANES) waves 2015 to 2016 and 2017 to March 2020 to observe pDDI prevalence between ritonavir-containing therapy and coadministered medications among US adults 18 years or older. CYP3A4-mediated medications were identified from affirmative medication questionnaire response and associated prescription examination by surveyors. CYP3A4-mediated medications with associated pDDIs with ritonavir and assessed pDDI severity (minor, major, moderate, and severe) were obtained from the University of Liverpool's COVID-19 online drug interaction checker, Lexicomp, a...
Source: Clinical Therapeutics - April 9, 2023 Category: Drugs & Pharmacology Authors: Ebuwa Igho-Osagie Kaylen Brzozowski Harry Jin Jeffrey Brown Marissa Grifasi Williams Amy Puenpatom Source Type: research
